Rafferty Asset Management, LLC Myriad Genetics Inc Transaction History

Rafferty Asset Management, LLC

  • $29.7 Billion
  • Q3 2025

A detailed history of Rafferty Asset Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 112,785 shares of MYGN stock, worth $756,787. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112,785
Previous 112,948 0.14%
Holding current value
$756,787
Previous $599,000 36.06%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
SELL
$3.84 - $7.84 $625 - $1,277
-163 Reduced 0.14%
112,785 $815,000
Q2 2025

Aug 14, 2025
SELL
$3.84 - $8.84 $130,007 - $299,287
-33,856 Reduced 23.06%
112,948 $599,000
Q1 2025

May 14, 2025
SELL
$8.87 - $14.98 $171,492 - $289,623
-19,334 Reduced 11.64%
146,804 $1.3 Million
Q4 2024

Feb 14, 2025
BUY
$13.17 - $27.03 $733,437 - $1.51 Million
55,690 Added 50.42%
166,138 $2.28 Million
Q3 2024

Nov 13, 2024
BUY
$23.97 - $28.6 $407,298 - $485,971
16,992 Added 18.18%
110,448 $3.02 Million
Q2 2024

Aug 13, 2024
SELL
$17.98 - $25.47 $2.8 Million - $3.97 Million
-155,747 Reduced 62.5%
93,456 $2.29 Million
Q1 2024

May 13, 2024
BUY
$17.59 - $23.59 $1.37 Million - $1.84 Million
77,804 Added 45.39%
249,203 $5.31 Million
Q4 2023

Feb 13, 2024
SELL
$13.91 - $21.32 $515,852 - $790,652
-37,085 Reduced 17.79%
171,399 $3.28 Million
Q3 2023

Nov 13, 2023
BUY
$15.99 - $23.22 $195,589 - $284,027
12,232 Added 6.23%
208,484 $3.34 Million
Q2 2023

Aug 11, 2023
BUY
$17.56 - $23.76 $463,777 - $627,525
26,411 Added 15.55%
196,252 $4.55 Million
Q1 2023

May 11, 2023
SELL
$15.26 - $23.75 $556,867 - $866,685
-36,492 Reduced 17.69%
169,841 $3.95 Million
Q4 2022

Feb 13, 2023
BUY
$14.51 - $20.99 $508,560 - $735,678
35,049 Added 20.46%
206,333 $2.99 Million
Q3 2022

Nov 14, 2022
BUY
$18.21 - $27.88 $1.14 Million - $1.74 Million
62,482 Added 57.43%
171,284 $3.27 Million
Q2 2022

Aug 12, 2022
SELL
$16.45 - $25.88 $364,943 - $574,147
-22,185 Reduced 16.94%
108,802 $1.98 Million
Q1 2022

May 13, 2022
SELL
$22.67 - $28.01 $1.04 Million - $1.29 Million
-45,935 Reduced 25.96%
130,987 $3.3 Million
Q4 2021

Feb 10, 2022
BUY
$24.13 - $32.63 $2.01 Million - $2.71 Million
83,152 Added 88.68%
176,922 $4.88 Million
Q3 2021

Nov 10, 2021
BUY
$29.97 - $36.66 $180,779 - $221,133
6,032 Added 6.88%
93,770 $3.03 Million
Q2 2021

Aug 10, 2021
SELL
$25.39 - $32.61 $497,999 - $639,612
-19,614 Reduced 18.27%
87,738 $2.68 Million
Q1 2021

May 10, 2021
BUY
$19.92 - $31.6 $1.73 Million - $2.75 Million
86,871 Added 424.15%
107,352 $3.27 Million
Q4 2020

Feb 10, 2021
SELL
$12.16 - $19.77 $730,414 - $1.19 Million
-60,067 Reduced 74.57%
20,481 $405,000
Q3 2020

Nov 13, 2020
BUY
$11.25 - $14.75 $309,487 - $405,772
27,510 Added 51.87%
80,548 $1.05 Million
Q2 2020

Aug 07, 2020
BUY
$10.69 - $16.49 $459,028 - $708,080
42,940 Added 425.23%
53,038 $601,000
Q1 2020

May 15, 2020
SELL
$9.78 - $29.53 $739,945 - $2.23 Million
-75,659 Reduced 88.22%
10,098 $145,000
Q4 2019

Feb 10, 2020
SELL
$20.93 - $35.1 $1.17 Million - $1.97 Million
-56,088 Reduced 39.54%
85,757 $2.34 Million
Q3 2019

Nov 14, 2019
SELL
$22.08 - $47.08 $598,522 - $1.28 Million
-27,107 Reduced 16.04%
141,845 $4.06 Million
Q2 2019

Aug 09, 2019
BUY
$22.67 - $35.0 $504,679 - $779,170
22,262 Added 15.18%
168,952 $4.69 Million
Q1 2019

May 15, 2019
BUY
$26.93 - $34.7 $3.95 Million - $5.09 Million
146,690 New
146,690 $4.87 Million
Q4 2018

Feb 11, 2019
SELL
$27.23 - $45.56 $477,015 - $798,120
-17,518 Closed
0 $0
Q3 2018

Nov 09, 2018
BUY
$37.57 - $50.34 $658,151 - $881,856
17,518 New
17,518 $806,000

Others Institutions Holding MYGN

# of Institutions
239
Shares Held
92.2M
Call Options Held
86.1K
Put Options Held
18.9K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $541M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email